Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.80 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159592 | 0.98 | MAPT (0.83) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL30197402 | 0.98 | MAPT (0.83) | MAPTKDM4EGAAPKMTSHR | |
| Hydrochloric Acid SCHEMBL2475806 | 0.95 | MAPT (0.88) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL1247565 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL31038567 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL1247271 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL807372 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL19054921 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL22387084 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR | |
| SCHEMBL16772950 | 0.91 | MAPT (0.96) | MAPTKDM4EGAAPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-1664035-B1 | 2,4 DI(HETERO)-ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2266977-A1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1664035-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026158-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | ZAP70, SYK, BTK | MAPT 4655/4885KDM4E 1335/4885GAA 2353/4885 |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | ZAP70, SYK, BTK | MAPT 4575/4885KDM4E 1162/4885GAA 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.